Drug-Induced Cognitive Impairment
Drug Safety · 2025-04 · 48 (4) · 339-361
DOI: 10.1007/s40264-024-01506-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Safety, online erschienen am 24.12.2024. Verfasst von Arne Reimers und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Box 117, 22100, Lund, Sweden. arne.reimers@med…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Drug-Related Side Effects and Adverse Reactions, Cognition Disorders. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 275 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lund University.
Abstract (Originalsprache)
Drug-induced cognitive impairment (DICI) is a well-established, yet under-recognised, complication of many types of pharmacological treatment. While there is a large body of scientific literature on DICI, most papers are about drug-induced dementia in the elderly and one specific drug class. However, DICI also comprises subclinical symptoms, domain-specific forms of cognitive impairment as well as mild cognitive impairment (MCI), and delirium. Even mild forms of DICI, if not recognised as such, can have deleterious and life-long consequences. In addition, DICI also occurs in younger adults and in children, and has been reported with many different drug classes. The aim of this review is to raise awareness of DICI by providing an overview on the type(s) and symptoms of observed DICI and the suspected underlying mechanism(s) for various drug classes: antiseizure medications, antidepressants, antiparkinsonian drugs, antipsychotics, lithium, benzodiazepines/Z-drugs, opioids, first-generation antihistamines, drugs for urinary incontinence, proton pump inhibitors, glucocorticoids, NSAIDs, statins, antihypertensives, and chemotherapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Box 117, 22100, Lund, Sweden. arne.reimers@med.lu.se.
- Department of Clinical Chemistry and Pharmacology, Skåne University Hospital, 22185, Lund, Sweden. arne.reimers@med.lu.se.
- Division of Neurology, Department of Clinical Sciences Lund, Lund University, Box 117, 22100, Lund, Sweden.
- Department of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skåne University Hospital, 22185, Lund, Sweden.
ORCID-Profile: Arne Reimers, Per Odin, Hanna Ljung
Förderung
- Lund University
Zitieren
APA
Reimers, A., Odin, P., & Ljung, H. (2025). Drug-Induced Cognitive Impairment. Drug Safety, 48(4), 339-361. https://doi.org/10.1007/s40264-024-01506-5
Vancouver
Reimers A, Odin P, Ljung H. Drug-Induced Cognitive Impairment. Drug Safety. 2025;48(4):339-361. doi:10.1007/s40264-024-01506-5
BibTeX
@article{Reimers2025,
author = {Reimers, Arne and Odin, Per and Ljung, Hanna},
title = {Drug-Induced Cognitive Impairment},
journal = {Drug Safety},
year = {2025},
volume = {48},
number = {4},
pages = {339--361},
doi = {10.1007/s40264-024-01506-5}
}
EUVIMED